Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Window For Effective Stroke Treatment Expanded
Once symptoms start, there"s only a tiny window of time for stroke victims to get life-saving treatment. Now, research from the Stanford University School of Medicine has cracked that window open a bit wider.

Houston Task Force To Target Hispanic Residents For HIV Testing
The Latino HIV Task Force in Houston will offer free HIV testing as part of National HIV Testing Day on June 27, the Houston Chronicle reports. According to the Houston Department of Health and Human Services (HDHHS), Hispanics comprise 21 percent of the more than 16,000 HIV cases reported to the agency over the last 10 years and 17 percent of the nearly 26,000 AIDS cases since 1981. Porfirio Villarreal, HDHHS"s public information officer and media chair for the Task Force, said that HIV prevention is challenging among Hispanic communities because of stigma and difficulties in talking openly about sex. He added, "People who are undocumented in this country do not go test because they fear they may be deported, which is wrong." The task force was established in 2002 and has brought together several local health agencies and community-based organizations that offer medical treatment or programs focused on HIV/AIDS, according to the Chronicle (Lamkahouan, Houston Chronicle, 6/22).
News of the day
Male Retirement Age And Dementia
British scientists have found a significant link between later retirement age and later onset of dementia in men.
Cardiovascular

BSD Receives FDA Humanitarian Use Designation For The BSD-2000 Hyperthermia System

BSD Medical Corporation (NASDAQ:BSDM) announced that the U.S. Food and Drug Administration (FDA) has granted Humanitarian Use Device (HUD) designation for the company"s BSD-2000 Hyperthermia System for use in conjunction with radiation therapy for the treatment of cervical carcinoma patients who are ineligible for chemotherapy. This is the first of the two steps required to obtain Humanitarian Device Exemption (HDE) marketing approval, which requires BSD Medical to demonstrate the device"s safety and probable benefit in treating a disease or condition that affects fewer than 4,000 individuals in the United States per year. Now that FDA has granted the Humanitarian Use Designation for the BSD-2000, which confirms that the intended use population is fewer than 4,000 patients per year, BSD can file an HDE submission with the FDA. FDA has 75 days from the date of receipt of the HDE submission to grant or deny an HDE application. This period includes a 30-day filing period during which FDA determines whether the HDE application is sufficiently complete to permit substantive review. During this review, FDA may refine the indications for use which received HUD designation to finalize the indications for use for which HDE approval will be granted. This decision will be based on the data that are available to support the device"s HDE application. The company believes that the data previously submitted to FDA and reviewed by the agency in the company"s pending PMA application can be used to support the HDE approval, and that this previous review may expedite marketing approval for the BSD-2000. Due to the lengthy nature of the PMA review process, the length of time that the submission has been under review by the FDA, and the company"s strong desire to bring the BSD-2000 to market as quickly as possible, the company has been working closely with FDA to seek the most expeditious pathway that can lead to marketing approval for the BSD-2000. FDA recommended that BSD pursue a Humanitarian Device Exemption (HDE) marketing approval and BSD followed FDA"s recommendation. The HDE approval of the BSD-2000 Hyperthermia System will authorize the commercial sale of the BSD-2000 in the United States. In addition, a product can have multiple HDE approvals and the company may decide to pursue additional HDE approvals for the BSD-2000 in the future. Cervical cancer is the second-most common cancer in women worldwide and a leading cause of death. It is the leading cause of death from cancer among women in developing countries. Researchers have predicted that developing countries could face a 75% increase in the number of cervical cancer cases in the next two decades due to growth and aging of the population. BSD is increasing the company"s representation in countries throughout the world, including the developing countries. BSD Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009